Gland Pharma Limited has informed the Exchange regarding a press release dated August 05, 2025, titled "Q1Fy26 Results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported Q1FY26 (quarter ended June 30, 2025) consolidated revenue of ₹15,056 crore, up 7% year-on-year and 6% quarter-on-quarter. Profit after tax surged 50% YoY to ₹2,155 crore, with PAT margin expanding 405 basis points to 14%. EBITDA grew 39% YoY to ₹3,678 crore with margins improving to 24% from 19% a year ago. Geographically, Europe (up 29%), Canada/Australia/NZ (up 65%), and India (up 13%) drove growth, while USA revenue dipped 2% YoY. Subsidiary Cenexi turned in an EBITDA breakeven of ₹86 crore versus a loss of ₹286 crore last year, and the company expanded GLP-1 capacity from 40 million to 140 million units.
A strong quarter with broad-based margin expansion and a turnaround at Cenexi should be viewed positively by shareholders. The 50% PAT growth, improving profitability, and pipeline momentum (12 new launches, capacity expansion) reinforce confidence in the company's growth trajectory, though the slight USA revenue softness is a point to watch.